
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc. is positioned favorably due to its focus on developing novel therapeutics addressing significant unmet medical needs, particularly in oncology and COVID-19. The company’s lead drug, Endoxifen, along with its COVID-19 treatments AT-H201 and AT-301, have potential to create substantial value, supported by attractive current valuations that suggest upside from the current share price. Additionally, anticipated key clinical milestones and data may serve as critical catalysts for enhancing investor confidence and driving stock performance.
Bears say
Atossa Therapeutics Inc reported a net loss of $8.4 million, translating to an earnings per share (EPS) of $(0.07), which was below both internal and consensus estimates of $(0.06). The company faces multiple significant risks including liquidity challenges, potential failures in clinical trials for its drug candidates, and hurdles in obtaining regulatory approvals and reimbursement for its products. Furthermore, increased competition and shifting investor sentiment toward biotech stocks may compound the already challenging landscape for Atossa, heightening the overall uncertainty surrounding its financial outlook.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares